Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Dreicer on Resistance to Antiandrogen Therapy in Prostate Cancer

September 8th 2016

Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses resistance to antiandrogen therapy in prostate cancer.

Dr. Levine on Evolving Treatment Options for Patients With mCRPC

September 5th 2016

Richard M. Levine, MD, medical director, Moffitt International Plaza, Moffitt Cancer Center, discusses the available agents and their benefits for patients with metastatic castration-resistant prostate cancer.

Dr. Johnstone on Immediate Salvage Therapy for Prostate Cancer

September 2nd 2016

Peter A. Johnstone, MD, vice chair, Department of Radiation Oncology, Moffitt Cancer Center, discusses immediate salvage therapy for patients with prostate cancer and the most common physician questions surrounding the treatment.

Levine Lends Advice on Treating Patients With mCRPC

August 26th 2016

Richard Levine, MD, discusses the selection of therapies available for patients with metastatic castration-resistant prostate cancer and the next steps in the field.

Researcher Explores Biologic Basis for Disparities in Prostate Cancer Outcomes

August 26th 2016

Kosj Yamoah, MD, discusses health disparities in prostate cancer and unanswered questions researchers still need to tackle.

Accurate Risk Status Assessment Critical to Prostate Cancer Care

August 25th 2016

Julio Pow-Sang, MD, discusses the significance of assessing risk status, options for patients with prostate cancer whose risk status falls in a "grey-zone," and how technology is helping oncologists more accurately characterize risk.

Expert Discusses Novel Therapies, Biomarkers in mCRPC

August 25th 2016

Jingsong Zhang, MD, PhD, discusses his vision for treating patients with metastatic castration-resistant prostate cancer.

Understanding the Rationale for Bone-Targeted Therapy in mCRPC

August 23rd 2016

Conor Lynch, PhD, sheds light on the biology of bone metastases as well as the mechanism of action for bone-directed therapies for patients with metastatic castration-resistant prostate cancer.

Pfizer Oncology Reach Expanding With Medivation Acquisition

August 22nd 2016

Pfizer has announced plans to acquire the biopharmaceutical company Medivation, which is the developer of the androgen receptor inhibitor enzalutamide (Xtandi).

Psychological Effects From ADT a Growing Challenge in Prostate Cancer

August 22nd 2016

Heather Jim, MD, describes the psychological impacts of testosterone-lowering drugs for patients with prostate cancer—and what oncologists should do to help.

Expert Offers Insight on Postoperative Radiation in Prostate Cancer

August 19th 2016

Peter Johnstone, MD, provides insight on post-prostatectomy radiation therapy for patients with prostate cancer.

Second-Line Therapies for mCRPC Complicated by Drug Interactions and Dosing Issues

August 18th 2016

Approximately 4 years after the FDA approval of 2 powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis raised issues complicating treatment with the 2 drugs, as well as what oncologists do not yet know.

Custirsen Combo Falls Short in Phase III mCRPC Trial

August 16th 2016

Adding custirsen to cabazitaxel (Jevtana) and prednisone in the second-line setting failed to improve overall survival in men with metastatic castration-resistant prostate cancer in the phase III AFFINITY trial.

Combo Trials Aim to Clarify Optimal Radium-223 Use in mCRPC

August 16th 2016

Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC

August 11th 2016

Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Immunotherapy Advances Again Propel Progress in GU Malignancies

August 11th 2016

Randy F. Sweis, MD, covers the immunotherapy advancements in prostate cancer, renal cell carcinoma, and bladder cancer, and what refinement lies ahead in each of these areas.

Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer

August 7th 2016

Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.

Caring for US Veterans Helped Lead Iraqi Immigrant to Develop Prostate Cancer Advances

August 6th 2016

Maha H. Hussain, MB ChB, whose work has helped advance treatment and care of men with prostate cancer, was honored in the Genitourinary Cancer category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to recognize leaders in the field.

Dr. Luke Nordquist on Radium-223 Retreatment

August 4th 2016

Luke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).

Expert Defends Merits of Prostatectomy

August 2nd 2016

Gregory Zagaja, MD, discusses the benefits of radical prostatectomy and other ongoing developments with surgery in prostate cancer.